IBIO

IBIO-200/201

COVID-19 Vaccine

Stage (next event)

Expected Date

Preclinical

TBD

Catalyst Info & Data Links

SLIDES


Mechanism of Action

MECHANISM OF ACTION 

  • It is a Virus-Like Particle (VLP) 

  • SARS-CoV-2 derived antigen is fused to a self-assembling protein partner to generate the VLP

  •  Antigen is displayed in a repetitive structure and geometry, and the particle is decorated with oligomannose so as to resemble the structure of a naturally occurring virus

  • More info on Slide 20

Last Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

NBRV down 16.6% Today - Market Remains Tough on Companies Developing New Antibiotics

Nabriva Therapeutics: One Of The Biggest Binary Events Of September

Paratek Pharmaceuticals Announces Positive Data for Omadacycline in Community-Acquired Bacterial Pne

Synthetic Biologics Reports Positive Ph2b Data for SYN-004

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon